Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00392327 · OUTCOME

The Estimated Full-scale IQ (FSIQ) at 9+/-3 Months Post Diagnosis for Medulloblastoma Patients

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET · Source last updated 2026-06-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Score on a scale
Interval / dispersion
Standard Deviation
Time frame
6 - 12 months post diagnosis

What was measured

Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 9+/-3 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better. Mean and standard deviation of FSIQ were calculated and reported.

Analysis population: Eligible medulloblastoma patients are included.

Groups in this outcome

Regimen A (Medulloblastoma Patients)

Medulloblastoma patients who received regimen A (no carboplatin / no isotretinoin)

Regimen B (Medulloblastoma Patients)

Medulloblastoma patients who received regimen B (carboplatin / no isotretinoin)

Regimen C (Medulloblastoma Patients)

Medulloblastoma patients who received regimen C (no carboplatin / isotretinoin)

Regimen D (Medulloblastoma Patients)

Medulloblastoma patients who received regimen D (carboplatin / isotretinoin)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Regimen A (Medulloblastoma Patients)22
Regimen B (Medulloblastoma Patients)30
Regimen C (Medulloblastoma Patients)13
Regimen D (Medulloblastoma Patients)23

Reported measurements

Source class 1
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Regimen A (Medulloblastoma Patients)96.620.54Not reportedNot reportedNot reported
Regimen B (Medulloblastoma Patients)89.117.45Not reportedNot reportedNot reported
Regimen C (Medulloblastoma Patients)83.515.22Not reportedNot reportedNot reported
Regimen D (Medulloblastoma Patients)94.816.88Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        20.54
        value
        96.6
      2. group Id
        OG001
        spread
        17.45
        value
        89.1
      3. group Id
        OG002
        spread
        15.22
        value
        83.5
      4. group Id
        OG003
        spread
        16.88
        value
        94.8
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    2. group Id
      OG001
      value
      30
    3. group Id
      OG002
      value
      13
    4. group Id
      OG003
      value
      23
    units
    Participants
description
Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 9+/-3 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better. Mean and standard deviation of FSIQ were calculated and reported.
dispersion Type
Standard Deviation
groups
  1. description
    Medulloblastoma patients who received regimen A (no carboplatin / no isotretinoin)
    id
    OG000
    title
    Regimen A (Medulloblastoma Patients)
  2. description
    Medulloblastoma patients who received regimen B (carboplatin / no isotretinoin)
    id
    OG001
    title
    Regimen B (Medulloblastoma Patients)
  3. description
    Medulloblastoma patients who received regimen C (no carboplatin / isotretinoin)
    id
    OG002
    title
    Regimen C (Medulloblastoma Patients)
  4. description
    Medulloblastoma patients who received regimen D (carboplatin / isotretinoin)
    id
    OG003
    title
    Regimen D (Medulloblastoma Patients)
param Type
MEAN
population Description
Eligible medulloblastoma patients are included.
reporting Status
POSTED
time Frame
6 - 12 months post diagnosis
title
The Estimated Full-scale IQ (FSIQ) at 9+/-3 Months Post Diagnosis for Medulloblastoma Patients
type
SECONDARY
unit Of Measure
Score on a scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice